EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Allogeneic hematopoietic stem cell transplantation for VEXAS syndrome: A review and a case report

Kentaro Nagae, Hiroyuki Muranushi iD, Yasuhito Nannya, Takeshi Maeda

Clinical Hematology International · 26.05.2026 · 8 (2)

DOI: 10.46989/001c.161719 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Clinical Hematology International, online erschienen am 26.05.2026. Verfasst von Kentaro Nagae und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology/Oncology, Kurashiki Central Hospital, Kurashiki, Okayama, Japan. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is caused by somatic UBA1 mutations and frequently complicated by myelodysplastic syndrome (MDS). Conventional immunosuppressive and anti-inflammatory therapies are often ineffective, and allogeneic hematopoietic stem cell transplantation (allo-HSCT) is currently the only curative treatment, although its optimal timing and donor selection remain uncertain. Case Presentation A 67-year-old man with VEXAS syndrome and MDS harboring UBA1 (p.M41T) and EZH2 mutations, refractory to azacitidine and corticosteroids, successfully underwent allo-HSCT from a one-antigen–mismatched related donor. Post-transplant chronic graft-versus-host disease was well controlled with ruxolitinib. Methods and Results We reviewed eight studies comprising 45 allo-HSCT recipients with VEXAS syndrome. The median age at transplantation was 59 years, and patients had received a median of five prior systemic therapies. MDS was present in 53.3% of cases, while 42.2% underwent transplantation for VEXAS without overt hematologic malignancy. The most frequent UBA1 variant was p.Met41Val (37.8%). At last follow-up, 84.4% of patients were alive, with resolution of inflammatory manifestations in most cases.

Conclusion

Allo-HSCT represents a curative option for refractory VEXAS syndrome. Comprehensive genetic profiling may aid in identifying candidates for early transplantation. If early transplantation is required, human leukocyte antigen-mismatched donors may be selected.

Schlagwörter

Stichwörter der Autor:innen

EZH2 gene mutationLiterature reviewUBA1 mutationVEXAS syndromeallogeneic hematopoietic stem cell transplantation

Autor:innen und Institutionen

  • Department of Hematology/Oncology, Kurashiki Central Hospital, Kurashiki, Okayama, Japan.
  • Division of Hematopoietic Disease Control, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.

ORCID-Profile: Hiroyuki Muranushi

Zitieren

APA

Nagae, K., Muranushi, H., Nannya, Y., & Maeda, T. (2026). Allogeneic hematopoietic stem cell transplantation for VEXAS syndrome: A review and a case report. Clinical Hematology International, 8(2). https://doi.org/10.46989/001c.161719

Vancouver

Nagae K, Muranushi H, Nannya Y, Maeda T. Allogeneic hematopoietic stem cell transplantation for VEXAS syndrome: A review and a case report. Clinical Hematology International. 2026;8(2). doi:10.46989/001c.161719

BibTeX
@article{Nagae2026,
  author = {Nagae, Kentaro and Muranushi, Hiroyuki and Nannya, Yasuhito and Maeda, Takeshi},
  title = {Allogeneic hematopoietic stem cell transplantation for VEXAS syndrome: A review and a case report},
  journal = {Clinical Hematology International},
  year = {2026},
  volume = {8},
  number = {2},
  doi = {10.46989/001c.161719}
}
Kostenlos starten →